Effect of Smoking Cessation on Glycemic Control in Type 2 Diabetics

November 12, 2024 updated by: Alhasnaa Mohamed Abdo Rawy, Assiut University

Effect of Smoking Cessation on Glycemic Control in Patients with Type 2 Diabetes

The goal of this observational study is to learn about the long-term effects of smoking cessation on glycemic control in type 2 diabetic patients The main question it aims to answer is:

Does smoking cessation lower HbA1c in type 2 diabetics on long term ? The participants will be counseled to cessate smoking and will be followed for 6 months and compared to control who will not cessate smoking .

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Smoking and diabetes are both major public health issues specially in our community. They act synergistically on morbidity and mortality. Diabetic smokers have much higher rates of micro and macrovascular complications. [Carole Clair et al., 2020] Approximately 1.3 billion people worldwide use tobacco, most commonly in the form of tobacco smoking, and more than 7 million people die every year as a result of smoking related conditions [Magdalena Walicka et al.,2022] Exposure to cigarette smoke is associated with vascular damage, endothelial dysfunction, and activation of oxidative stress, inflammatory pathways, coagulation, and fibrinolysis A similar mechanism of endothelial dysfunction is described for people with diabetes. It is therefore not surprising that smoking enhances the combined harmful effects of elevated blood glucose levels, accelerating vascular damage in diabetic patients who smoke The prevalence of current smoking was 45.5% in male patients with type 2 diabetes. The levels of fasting blood glucose and HbA1c increased with number of cigarettes smoked per day compared with non-smokers Smoking and its cessation showed dose- and time-dependent relationship with glycemic control and insulin resistance in patients with type 2 diabetes mellitus. These findings may highlight the importance of smoking cessation in the clinical management of diabetes mellitus.

the effect of smoking and its cessation on glycemic control in diabetic patients has not been fully examined yet.

There is lack of evidence regarding interventions for smoking cessation among individuals with diabetes

Study Type

Observational

Enrollment (Estimated)

178

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
      • Assuit, Egypt
        • Assuit university
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Community sample

Description

Inclusion Criteria:

- Moderate Somking index Having been diagnosed with a type 2 diabetes Being ≥ 35 years old HbA1c > 7

Exclusion Criteria:

Type 1 diabetes Drug induced Diabetes mellitus Type 2 diabetes on insulin treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
1_Case group 2_control group
  1. Case group diabetic smokers which will be counseled to cessate smoking
  2. Control group diabetic smokers which will refuse to cessate smoking
Behavioral: Smoking cessation counselling group
Case group will be counseled to cessate smoking and will be followed up with HbA1c
Case control group
Case group: diabetic smokers which will cessate smoking Control group: diabetic smokers which will refuse to cessate smoking

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Glycemic control after smoking cessation
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2024

Primary Completion (Estimated)

November 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

November 12, 2024

First Submitted That Met QC Criteria

November 12, 2024

First Posted (Estimated)

November 13, 2024

Study Record Updates

Last Update Posted (Estimated)

November 13, 2024

Last Update Submitted That Met QC Criteria

November 12, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • Smoking cessation and HbA1C

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Smoking Cessation

Clinical Trials on Smoking cessation counselling group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe